Clinical Trials Logo

Filter by:
NCT ID: NCT03521154 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer (Stage III)

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

LAURA
Start date: July 19, 2018
Phase: Phase 3
Study type: Interventional

A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

NCT ID: NCT03519971 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Start date: March 29, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC] CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

NCT ID: NCT03518086 Active, not recruiting - Ulcerative Colitis Clinical Trials

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Start date: June 18, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

NCT ID: NCT03505801 Active, not recruiting - Atrial Fibrillation Clinical Trials

Confirm Rx Insertable Cardiac Monitor SMART Registry

Start date: April 24, 2018
Phase:
Study type: Observational [Patient Registry]

The purpose of the Confirm Rx SMART Registry is to collect real world data to assess the safety and performance of the Confirm Rx Insertable Cardiac Monitor (ICM) and system over a 12 month period. A sub-set of subjects enrolled in the Confirm Rx SMART Registry will meet the Post Market Clinical Follow-Up (PMCF) requirement for CE mark.

NCT ID: NCT03484507 Active, not recruiting - Clinical trials for Acanthamoeba Keratitis

Parasitic Ulcer Treatment Trial Pilot

Start date: January 1, 2018
Phase: Phase 2
Study type: Interventional

This is a study of optimal treatments for acanthamoeba keratitis. In the first part of the study, participants will be randomized to chlorhexidine monotherapy or chlorhexidine plus povidone iodine. After four weeks of therapy, participants will be re-randomized to early corticosteroids, later corticosteroids, or placebo.

NCT ID: NCT03466411 Active, not recruiting - Crohn's Disease Clinical Trials

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

GALAXI
Start date: April 13, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

NCT ID: NCT03450525 Active, not recruiting - Trauma Clinical Trials

The Predictive Performance of Glasgow Coma Scale in Relation to Time

Start date: January 15, 2018
Phase:
Study type: Observational

The study aims to assess whether time between injury and first Glasgow Coma Scale measurement will affect its predictive value.

NCT ID: NCT03440372 Active, not recruiting - Crohn Disease Clinical Trials

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Start date: February 27, 2018
Phase: Phase 3
Study type: Interventional

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

NCT ID: NCT03438838 Active, not recruiting - Achalasia Cardia Clinical Trials

Randomised Trial Between LHM Alone Vs LHM With Anterior Fundoplication In Achalasia Cardia

Start date: January 24, 2018
Phase: N/A
Study type: Interventional

Back ground: Achalasia Cardia (AC) manifests with major symptom dysphagia. Surgery as the treatment modality relieves dysphagia in most of the patients. Laparoscopic Heller's myotomy(LHM) is the surgery of choice but is associated with gastroesophageal reflux. Anterior fundoplication (Dor Fundoplication) is usually combined with LHM in patients with AC. It reduces gastroesophageal reflux following LHM. It has been observed that along with reduction of gastroesophageal reflux Dor Fundoplication also affects relief of dysphagia. But it has not been prospectively studied. Hypothesis:The hypothesis of present study is that "Frequency of dysphagia following Laparoscopic Heller's myotomy with Dor fundoplication is more than that compared to Laparoscopic Heller's myotomy alone in patients with Achalasia Cardia". Methods: From December2017 to November 2018 minimum of 20 patients with diagnosis of Achalasia cardia will be randomized to receive either Laparoscopic Heller's myotomy (LHM) alone or LHM with Dor fundoplication. Symptomatic outcomes would be assessed using frequency of dysphagia and Eckardt's score. . Outcomes: Primary outcome is Frequency of dysphagia and secondary outcome is manometry pressure assessment. Statistical analysis would be done using Statistical Package for the Social Sciences (SPSS) soft ware. P value < 0.05 is considered significant.

NCT ID: NCT03431571 Active, not recruiting - Hypermetropia Clinical Trials

Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Hyperopia

V1601CI
Start date: July 5, 2017
Phase: N/A
Study type: Interventional

The correction of farsightedness using ReLEx SMILE for hyperopia is focus of this investigation. The objective is to evaluate the safety and effectiveness.